Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 13/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.62 |
| ▸ | NT5E | P21589 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20168620 | 0.94 | ADORA1 (0.62) | ADORA1ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL20167946 | 0.92 | ADORA3 (0.64) | ADORA1ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL21765921 | 0.88 | ADORA1 (0.62) | ADORA1ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL29493245 | 0.86 | ADORA1 (0.62) | ADORA1ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL20180072 | 0.86 | ADORA1 (0.62) | ADORA1ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL20168548 | 0.85 | ADORA3 (0.60) | ADORA1ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL21766009 | 0.85 | ADORA1 (0.60) | ADORA1ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL20180022 | 0.84 | NT5E (0.70) | ADORA1ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL20180324 | 0.83 | ADORA1 (0.60) | ADORA1ADORA3ADORA2AADORA2BNT5E | |
| SCHEMBL21766005 | 0.82 | ADORA1 (0.60) | ADORA1ADORA3ADORA2AADORA2BNT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267845-B2 | Inhibitors of CD73-mediated immunosuppression | ARCUS BIOSCIENCES, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20200062797-A1 | INHIBITORS OF CD73-MEDIATED IMMUNOSUPPRESSION | ARCUS BIOSCIENCES, INC. | 2020-02-27 | — | — | US | disclosed |
| EP-3541396-A1 | INHIBITORS OF CD73-MEDIATED IMMUNOSUPPRESSION | Arcus Biosciences, Inc. (US) | 2019-09-25 | — | — | EP | disclosed |
| WO-2018094148-A1 | INHIBITORS OF CD73-MEDIATED IMMUNOSUPPRESSION | ARCUS BIOSCIENCES, INC. (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062797-A1 | INHIBITORS OF CD73-MEDIATED IMMUNOSUPPRESSION | ENTPD5, NT5E, ENTPD1 | ADORA1 29/4885ADORA3 28/4885ADORA2A 13/4885 |
| US-11267845-B2 | Inhibitors of CD73-mediated immunosuppression | ENTPD5, NT5E, ENTPD1 | ADORA1 29/4885ADORA3 28/4885ADORA2A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.